SAICAR (hydrate)
(Synonyms: Succino-AICAR, Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5'-phosphate) 目录号 : GC48505An intermediate for purine synthesis
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
SAICAR is an intermediate in the de novo purine nucleotide synthesis pathway. It is reported to stimulate pyruvate kinase isoform M2 and to promote cancer cell survival in conditions of limited glucose availability.1
1.Keller, K.E., Tan, I.S., and Lee, Y.S.SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditionsScience3381069-1072(2012)
Cas No. | SDF | ||
别名 | Succino-AICAR, Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5'-phosphate | ||
Canonical SMILES | NC1=C(C(N[C@H](C(O)=O)CC(O)=O)=O)N=CN1[C@H]2[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O2.O | ||
分子式 | C13H19N4O12P•XH2O | 分子量 | 454.3 |
溶解度 | Methanol: Slightly Soluble,Water: Slightly Soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2012 mL | 11.0059 mL | 22.0119 mL |
5 mM | 0.4402 mL | 2.2012 mL | 4.4024 mL |
10 mM | 0.2201 mL | 1.1006 mL | 2.2012 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Cloning, expression, purification, crystallization and preliminary X-ray crystallographic study of the putative SAICAR synthetase (PH0239) from Pyrococcus horikoshii OT3
Acta Crystallogr Sect F Struct Biol Cryst Commun 2010 Feb 1;66(Pt 2):180-3.PMID:20124717DOI:PMC2815687
The study of proteins involved in de novo biosynthesis of purine nucleotides is central in the development of antibiotics and anticancer drugs. In view of this, a protein from the hyperthermophile Pyrococcus horikoshii OT3 was isolated, purified and crystallized using the microbatch method. Its primary structure was found to be similar to that of SAICAR synthetase, which catalyses the seventh step of de novo purine biosynthesis. A diffraction-quality crystal was obtained using Hampton Research Crystal Screen II condition No. 34, consisting of 0.05 M cadmium sulfate hydrate, 0.1 M HEPES buffer pH 7.5 and 1.0 M sodium acetate trihydrate, with 40%(v/v) 1,4-butanediol as an additive. The crystal belonged to space group P3(1), with unit-cell parameters a = b = 95.62, c = 149.13 A. Assuming the presence of a hexamer in the asymmetric unit resulted in a Matthews coefficient (V(M)) of 2.3 A(3) Da(-1), corresponding to a solvent content of about 46%. A detailed study of this protein will yield insights into structural stability at high temperatures and should be highly relevant to the development of antibiotics and anticancer drugs targeting the biosynthesis of purine nucleotides.